|
Typ |
Publikácia |
3 |
Časopis |
Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
36 |
Časopis |
Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426. |
59 |
Časopis |
Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196. |
62 |
Časopis |
Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125. |
63 |
Časopis |
Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812. |
73 |
Časopis |
Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159. |
81 |
Časopis |
Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678. |
92 |
Časopis |
Lee CY, Mauro VF, Alexander KS. Visual and spectrophotometric determination of compatibility of alteplase and streptokinase with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 606-608. |
93 |
Časopis |
Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188. |
99 |
Časopis |
Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
132 |
Časopis |
Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184. |
176 |
Časopis |
Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568. |
182 |
Časopis |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60. |
187 |
Časopis |
Olsen KM, Gurley BJ, Davis GA, Christensen R, Monaghan MS. Stability of flumazenil with selected drugs in 5% dextrose injection. Am J Hosp Pharm 1993 ; 50: 1907-1912. |
192 |
Časopis |
Peddicord TE, Olsen KM, ZumBrunnen TL, Warner DJ, Webb L. Stability of high-concentration dopamine hydrochloride, norepinephrine bitartrate, epinephrine hydrochloride, and nitroglycerin in 5% dextrose injection. Am J Health-Syst Pharm 1997 ; 54: 1417-1419. |
196 |
Časopis |
Pramar Y, Das Gupta V, Neal Gardner S, Yau B. Stabilities of dobutamine, dopamine, nitroglycerin and sodium nitroprusside in disposable plastic syringes. J Clin Pharm Ther 1991 ; 16: 203-207. |
197 |
Časopis |
Allwood MC. The stability of four catecholamines in 5% glucose infusions. J Clin Pharm Ther 1991 ; 16: 337-340. |
198 |
Časopis |
Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520. |
199 |
Časopis |
Hassan E, Leslie J, Martir-Herrero ML. Stability of labetalol hydrochloride with selected critical care drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 2143-2145. |
206 |
Časopis |
Sautou-Miranda V, Gremeau I, Chamard I, Cassagnes J, Chopineau J. Stability of dopamine hydrochloride and of dobutamine hydrochloride in plastic syringes and administration sets. Am J Health-Syst Pharm 1996 ; 53: 186. |
210 |
Časopis |
Stewart JT, Warren FW, King AD. Stability of ranitidine hydrochloride and seven medications. Am J Hosp Pharm 1994 ; 51: 1802-1807. |
214 |
Časopis |
Galante LJ, Stewart JT, Warren FW, Edgar JW, Huff AJ. Stability of ranitidine hydrochloride with eight medications in intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 1606-1610. |
215 |
Časopis |
Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426. |
240 |
Časopis |
Lam XM, Ward CA, de C du M?e CPR. Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy. Am J Health-Syst Pharm 1995 ; 52: 1904-1909. |
249 |
Časopis |
Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
251 |
Časopis |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
255 |
Časopis |
Ishisaka DY. Visual compatibility of fluconazole with drugs given by continuous infusion. Am J Hosp Pharm 1994 ; 51: 2290,2292. |
266 |
Časopis |
Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855. |
280 |
Časopis |
Allen LV, Stiles ML, Prince SJ, Sylvestri MF. Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2427-2433. |
288 |
Časopis |
Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962. |
295 |
Časopis |
Yamashita SK, Walker SE, Choudhury T, Iazzetta J. Compatibility of selected critical care drugs during Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1048-1051. |
299 |
Časopis |
Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
300 |
Časopis |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
301 |
Časopis |
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
314 |
Časopis |
Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65. |
315 |
Časopis |
Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600. |
316 |
Časopis |
Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613. |
317 |
Časopis |
Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362. |
336 |
Časopis |
Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409. |
337 |
Časopis |
Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533. |
377 |
Časopis |
Pereira-Rosario R, Utamura T, Perrin JH. Interaction of heparin sodium and dopamine hydrochloride in admixtures studied by microcalorimetry. Am J Hosp Pharm 1988 ; 45: 1350-1352. |
384 |
Časopis |
Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632. |
386 |
Časopis |
Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358. |
396 |
Časopis |
Chilvers MR, Lysne JM. Visual compatibility of ranitidine hydrochloride with commonly used critical-care medications. Am J Hosp Pharm 1989 ; 46: 2057-2058. |
398 |
Časopis |
Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557. |
402 |
Časopis |
Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821. |
403 |
Časopis |
Outman WR, Monolakis J. Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 1539-1541. |
467 |
Časopis |
Ishisaka DY, van Vleet J, Marquardt E. Visual compatibility of indomethacin sodium trihydrate with drugs given to neonates by continuous infusion. Am J Hosp Pharm 1991 ; 48: 2442-2443. |
479 |
Časopis |
Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966. |
524 |
Časopis |
Farquhar Zanetti LA. Visual compatibility of diltiazem with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1992 ; 49: 1911. |
619 |
Časopis |
Kirschenbaum HL, Aronoff W, Perentesis GP, Plitz GW, Cutie AJ. Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drugs additives. Am J Hosp Pharm 1982 ; 39: 1013-1015. |
660 |
Časopis |
Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232. |
705 |
Časopis |
Lee YC, Malick W, Amann AH, Baaske DM, Shah JJ, Wagenknecht DM, Carter JE. Bretylium tosylate admixture compatibility. II : Dopamine, lidocaine, procainamide, and nitroglycerin. Am J Hosp Pharm 1981 ; 38: 183-187. |
732 |
Časopis |
Gardella LA, Zaroslinski JF, Possley LH. Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 1: Stability with common intravenous fluids. Am J Hosp Pharm 1975 ; 32: 575-578. |
738 |
Časopis |
Gardella LA, Kesler H, Amann A, Carter JE. Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 3: Stability with miscellaneous additives. Am J Hosp Pharm 1978 ; 35: 581-584. |
813 |
Časopis |
Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68. |
891 |
Časopis |
Matsuura G. Visual compatibility of sargramostim (GM-CSF) during simulated Y-site administration with selected agents. Hosp Pharm 1992 ; 27: 200, 202, 209. |
921 |
Časopis |
Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292. |
925 |
Časopis |
Dupuis LL, Trope A, Giesbrecht E, Wong B. Compatibility and stability of propafenone hydrochloride with five critical-care medications. Can J Hosp Pharm 1998 ; 51: 55-57. |
939 |
Časopis |
Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170. |
963 |
Časopis |
Schaaf LJ, Tremel LC, Wulf BG, Vernon KK. Compatibility of enalaprilat with dobutamine, dopamine, heparin, nitroglycerin, potassium chloride and nitroprusside. J Clin Pharm Ther 1990 ; 15: 371-376. |
1036 |
Časopis |
Hasegawa GR, Eder JF. Visual compatibility of amiodarone hydrochloride injection with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 1379-1380. |
1041 |
Časopis |
Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951. |
1049 |
Časopis |
Klamerus KJ, Ueda CT, Newton DW. Stability of nitroglycerin in intravenous admixtures. Am J Hosp Pharm 1984 ; 41: 303-305. |
1057 |
Časopis |
Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207. |
1058 |
Časopis |
Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ. Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm 1983 ; 40: 1690-1691. |
1072 |
Časopis |
Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459. |
1221 |
Časopis |
Dahlin PA, Paredes SM. Visual compatibility of dobutamine with seven parenteral drug products. Am J Hosp Pharm 1980 ; 37: 460,464. |
1228 |
Časopis |
Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381. |
1249 |
Časopis |
Dandurand KR, Stennett DJ. Stability of dopamine hydrochloride exposed to blue-light phototherapy. Am J Hosp Pharm 1985 ; 42: 595-597. |
1315 |
Časopis |
Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297. |
1338 |
Časopis |
Baptista RJ, Dumas GJ, Bistrian BR, Condella F, Blackburn GL. Compatibility of total nutrient admixtures and secondary cardiovascular medications. Am J Hosp Pharm 1985 ; 42: 777-778. |
1397 |
Časopis |
Garner ST, Murdoch JM. Dopamine dilutions. Pharm J 1990 ; 244: 218. |
1410 |
Časopis |
Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145. |
1415 |
Časopis |
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74. |
1420 |
Časopis |
Bergquist PA, Hunke WA, Reed RA, Manas D, Forsyth RJ, Kenney RR, Cook J, Holahan M. Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration. J Clin Pharm Ther 1999 ; 24: 125-132. |
1423 |
Časopis |
Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518. |
1490 |
Časopis |
Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254. |
1496 |
Časopis |
Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428. |
1506 |
Časopis |
Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D. Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units. EJHP 2015 ;22:107-112. |
1508 |
Časopis |
Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124. |
1512 |
Laboratórium |
Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015 |
1625 |
Časopis |
Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321. |
1662 |
Časopis |
Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37. |
1698 |
Časopis |
Körner A, Bonnacker I. Stabilität von dopaminhydrochlorid (Dopamine Solvay°) in mischungen mit infusionlösungen. Krankenhauspharmazie 1997 ; 18: 474-478. |
1703 |
Časopis |
Schuster F, Bernard R. Kompatibilität von enalaprilat i.v. mit ausgewählten arzneimitteln. Krankenhauspharmazie 1995 ; 16: 101-103. |
1712 |
Časopis |
Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233. |
1713 |
Časopis |
Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315. |
1721 |
Časopis |
Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72. |
1754 |
Časopis |
Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244. |
1801 |
Časopis |
Feddema S, Rusho WJ, Tyler LS, Barker B. Physical compatibility of vasopressin with medications commonly used in cardiac arrest. Am J Health-Syst Pharm 2003 ; 60: 1271-1272. |
1803 |
Časopis |
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85. |
1820 |
Časopis |
Braenden JU, Stendal TL, Fagernaes CB. Stability of dopamine hydrochloride 0.5 mg/ml in polypropylene syringes. J Clin Pharm Ther 2003 ; 28: 471-474. |
1902 |
Časopis |
Walker SE, Wyllie A, Law S. Physical compatibility of pantoprazole with selected medications during simulated Y-site administration. Can J Hosp Pharm 2004 ; 57, 2: 90-96. |
1925 |
Časopis |
Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519. |
1937 |
Časopis |
Lai JJ, Brodeur SK. Physical and chemical stability of daptomycin with nine medications. Ann Pharmacotherapy 2004 ; 38: 1612-1616. |
1944 |
Časopis |
Hartman CA, Faria CE, Mago K. Visual compatibility of bivalirudin with selected drugs. Am J Health-Syst Pharm 2004 ; 61: 1774. |
1953 |
Časopis |
Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
1964 |
Časopis |
Hartman CA, Baroletti SA, Churchill WW et al. Visual compatibility of argatroban with selected drugs. Am J Health-Syst Pharm 2002 ; 59: 1784-1785. |
1965 |
Časopis |
Brustugun J, Kristensen S, Tonnesen HH. Photostability of sympatomimetic agents in commonly used infusion media in the absence and presence of bisulfite. PDA J Pharm Sci Technol 2004 ; 58, 6: 296-308. |
1982 |
Časopis |
Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837. |
2017 |
Časopis |
Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976. |
2018 |
Časopis |
Veggeland T. Visual compatibility of clonidine with selected drugs. Am J Health-Syst Pharm 2005 ; 62: 1968-1969. |
2090 |
Časopis |
Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196. |
2108 |
Časopis |
Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232. |
2109 |
Časopis |
Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75. |
2141 |
Časopis |
Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658. |
2192 |
Časopis |
Cochran BG, Sowinski KM, Fausel C, Overholser BR. Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs. Am J Health-Syst Pharm 2007 ; 64, 13: 1410-1414. |
2231 |
Časopis |
de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388. |
2233 |
Časopis |
Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457. |
2247 |
Časopis |
Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278. |
2262 |
Časopis |
Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265. |
2269 |
Časopis |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
2271 |
Laboratórium |
Daptomycine (Cubicin®) Résumé des caractéristiques du produits Novartis 2006 |
2879 |
Poster |
Imesch G., Humbert-Delaloye V., Berger M., Pannatier A. Compatibilité entre amiodarone, catecholamines et/ou nitroprussiate de sodium, administré en continu par voie veineuse aux soins intensifs adultes. GSASA Congress - Lucerne - Switzerland 2008 |
3012 |
Časopis |
Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220. |
3152 |
Časopis |
Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644. |
3177 |
Poster |
Humbert-Delaloye V, Berger M, Pannatier A. Compatibilités physico-chimique entre catécholamines, amiodarone, et/ou nitroprussiate de sodium intraveineux. 16èmes JFSPH, Sion, 18-19 novembre 2010 2010 |
3201 |
Časopis |
Dice JE. Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit. J Pediatr Pharmacol Ther 2006 ; 11:233?6. |
3210 |
Časopis |
Jasti Bhaskara R, Saraf Poonam. Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. Int J Pharm Compound 2011 ; 15, 3: 259-261. |
3216 |
Časopis |
Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18 |
3249 |
Časopis |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
3254 |
Časopis |
Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270. |
3332 |
Laboratórium |
Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012 |
3372 |
Časopis |
Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anestesiol 2013 ; 63, 1: 163-166. |
3381 |
Časopis |
Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Gattlen L, Pannatier A. In vitro compatibility of various cardioactive drugs during simulated Y-site administration. EJHP 2013 ; 20:110-116. |
3385 |
Časopis |
Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182. |
3408 |
Časopis |
Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21. |
3595 |
Laboratórium |
Aciclovir - Summary of Product Characteristics Hospira 2009 |
3638 |
Laboratórium |
Dopamin (Dopamine 40 mg/mL sterile concentrate®) - Summary of Product Characteristics Hospira 2010 |
3712 |
Časopis |
Ghanayem N.S, Lee L, Nelson T, Wong S, Gordon G.B, Markdante K et al. Stability of dopamine and epinephrine solutions up to 84 hours. Pediatr Crit Care Med 2001 ; 2, 4: 315-317. |
3715 |
Časopis |
Mauro V.F, Howard M.S, Boddu S.H.S, Churchwell M.D. Compatibility of conivaptan injection with select cardiovascular medications. Am J Health-Syst Pharm 2014 ; 71:1534-1535 |
3759 |
Časopis |
Igarashi K, Kawahara M. Examination of the cause of changing solution color by mixing aminophylline and dopamine, the compatibility of which was indicated by the supplier. Yakugaku Zasshi 2014 ; 134, 2: 293-298. |
3766 |
Časopis |
Forrest J.M, Hildgen P. Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165. |
3767 |
Časopis |
Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172. |
3823 |
Časopis |
Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l’unité de soins intensifs
Pharmactuel 2015 ; 48, 3 : 146-152. |
3824 |
Časopis |
Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98 |
3827 |
Poster |
Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015 |
3828 |
Poster |
Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015 |
3829 |
Poster |
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015 |
3923 |
Časopis |
Luu Y, Thigpen J, Brown S.D. Stability of sildenafil in combination with heparin and dopamine. Am J Health-Syst Pharm 2017 ; 74, 1: e64-e71 |
3932 |
Laboratórium |
Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015 |
3942 |
Časopis |
Frank M.I, Boddu S.H.S, . Mauro V.F,. Churchwell M.D. Physical compatibility of valproate sodium injection with dobutamine and dopamine. Am J Health-Syst Pharm 2017 ; 74, 5: 280-281. |
3964 |
Časopis |
Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33. |
4055 |
Časopis |
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
4108 |
Časopis |
Cruz K, Chrchwell M, Mauro V, Boddu. Physical compatibility of levetiracetam injection with heparin, dobutamine, and dopamine. Am J Health-Syst Pharm 2018 ;75;8:510-512 |
4145 |
Časopis |
Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056 |
4319 |
Časopis |
Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337. |
4389 |
Časopis |
Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213 |
4407 |
Časopis |
Bustin A, Ramsey Z, Hanna B, Kaushal G. Compatibility of treprostinil sodium and dopamine hydrochloride during simulated Y-site administration. Am J Health-Syst Pharm 2020 ;77,8:649–657. |
4433 |
Časopis |
Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485. |
4434 |
Časopis |
Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170. |
4491 |
Časopis |
De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2020 |
4524 |
Poster |
Stucki C, Sautter A-M, Bonnabry P. Physical compatibility of the propofol emulsion with 33 drugs used in anaesthesiology. ESCP Symposium, Geneva, Switzerland 2009 |
4603 |
Časopis |
Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234. |
4650 |
Laboratórium |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021 |
4651 |
Časopis |
De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2021 ;180,1169–1176. |
4655 |
Časopis |
Holyk A, Lindner A, Lindner S, Shippert B Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration. Am J Health-Syst Pharm 2022 ;79,1:27-33 |
4742 |
Časopis |
Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255. |
4801 |
Časopis |
Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1: |
4818 |
Laboratórium |
Giapreza 2.5mg per ml concentrate for solution for infusion - Summary of Product Characteristics Updated 30-Jun-2022 PAION UK Ltd 2022 |
4832 |
Časopis |
Nilsson N, Storesund I, Tho I, Nezvalova‑Henriksen K. Co‑administration of drugs with parenteral nutrition in the neonatal intensive care unit—physical compatibility between three components. Eur J Pedia 2022 ; 181:2685–2693. |
4837 |
Časopis |
De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page‑Sharp N, Moore B.R, Batty K.T. Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. Eur J Clin Pharmacol 2024 ; 80:1079–1087. |